Skip to content
CNS Clinical Research

Ann Arbor, Michigan

CNS clinical trials in Ann Arbor, MI

47 CNS studies are recruiting participants at sites in Ann Arbor as of November 16, 2026, according to ClinicalTrials.gov. CNS Clinical Research can help you understand your options and connect with a study team.

Call (888) 520-7418
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Ann Arbor at a glance

  • 47 studies are recruiting at a site in Ann Arbor.
  • By phase: Phase 1 (2), Phase 1/2 (5), Phase 2 (11), Phase 3 (12), Phase 4 (2), No phase (10), Observational (5). Studies of devices and behavioral approaches have no phase.
  • By sponsor: industry (26), university, hospital or other (20), government (1).
  • By research area: Depression (13), Migraine (11), Parkinson's Disease (10), Epilepsy (7), Multiple Sclerosis (4), Bipolar Disorder (1), Schizophrenia (1).
  • Most recent update to one of these records: November 16, 2026.

Depression studies recruiting in Ann Arbor

Basic details from each study's public record (the 30 most recently updated of 47). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

    • Phase 2
    • Ages 18 to 80
    • All sexes
    Sponsor
    Reunion Neuroscience Inc
    Study site
    University of Michigan
    Registry record
    NCT07002034 · updated
  2. A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression

    • No phase
    • Ages 18 and older
    • All sexes
    Sponsor
    LivaNova
    Study site
    Michigan Clinical Research Institute PC
    Registry record
    NCT03887715 · updated
  3. E-Mindfulness Approaches for Living After Breast Cancer

    • Phase 3
    • Ages 18 to 50
    • All sexes
    Sponsor
    NRG Oncology
    Study site
    Trinity Health Saint Joseph Mercy Hospital Ann Arbor
    Registry record
    NCT06748222 · updated
  4. ALTO-207 in Adults With Treatment-resistant Depression (TRD)

    • Phase 2
    • Ages 18 to 75
    • All sexes
    Sponsor
    Alto Neuroscience
    Registry record
    NCT07553637 · updated
  5. ALTO-100 in Bipolar Disorder With Depression (BD-D)

    • Phase 2
    • Ages 18 to 70
    • All sexes
    Sponsor
    Alto Neuroscience
    Registry record
    NCT06656416 · updated

Source: ClinicalTrials.gov. Data processed . See every depression study recruiting in Ann Arbor, MI on ClinicalTrials.gov.

Schizophrenia studies recruiting in Ann Arbor

  1. A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia

    • Phase 2
    • Ages 18 to 65
    • All sexes
    Sponsor
    MapLight Therapeutics
    Registry record
    NCT07459647 · updated

Source: ClinicalTrials.gov. Data processed . See every schizophrenia study recruiting in Ann Arbor, MI on ClinicalTrials.gov.

Parkinson's disease studies recruiting in Ann Arbor

  1. DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

    • Phase 3
    • Ages 18 and older
    • Female participants
    Sponsor
    AstraZeneca
    Registry record
    NCT06989112 · updated
  2. Phase 2 Trial of Tributyrin in People With Parkinson's Disease and Cognitive Impairments

    • Phase 1/2
    • Ages 45 and older
    • All sexes
    Sponsor
    Prabesh Kanel
    Study site
    Domino's Farms
    Registry record
    NCT07154511 · updated
  3. Striatal and Extra-Striatal Cholinergic Terminal Density in LRRK2-PD Mutation

    • Observational
    • Ages 45 and older
    • All sexes
    Sponsor
    University of Michigan
    Study site
    University of Michigan
    Registry record
    NCT07642908 · updated
  4. Tributyrin for Progressive Supranuclear Palsy (PSP): Virtual Trial

    • Phase 1/2
    • Ages 45 and older
    • All sexes
    Sponsor
    Prabesh Kanel
    Study site
    Domino's Farms
    Registry record
    NCT07863180 · updated
  5. A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease

    • Phase 3
    • Ages 45 to 75
    • All sexes
    Sponsor
    BlueRock Therapeutics
    Study sites
    Michigan Clinical Research Unit - Neurology · University of Michigan Clinical Research Unit - Neurology
    Registry record
    NCT06944522 · updated
  6. A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations

    • Phase 2
    • Ages 30 to 80
    • All sexes
    Sponsor
    Appello Pharmaceuticals, Inc.
    Study site
    University of Michigan Health System (UMHS) (Site #202)
    Registry record
    NCT07432958 · updated
  7. A Pilot Study of In-lab Dynamic Standing in Parkinson's Disease

    • Phase 1
    • Ages 50 and older
    • All sexes
    Sponsor
    University of Michigan
    Study site
    Domino's Farms
    Registry record
    NCT07543861 · updated

Source: ClinicalTrials.gov. Data processed . See every Parkinson's disease study recruiting in Ann Arbor, MI on ClinicalTrials.gov.

Multiple sclerosis (MS) studies recruiting in Ann Arbor

  1. A Study of AZD0120 in Autoimmune Diseases

    • Phase 1/2
    • Ages 18 to 75
    • All sexes
    Sponsor
    AstraZeneca
    Registry record
    NCT07295847 · updated
  2. A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)

    • Observational
    • Ages 18 and older
    • All sexes
    Sponsor
    TG Therapeutics, Inc.
    Study site
    TG Therapeutics Investigational Trial Site
    Registry record
    NCT06433752 · updated
  3. A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    TG Therapeutics, Inc.
    Study site
    TG Therapeutics Investigational Trial Site
    Registry record
    NCT06680037 · updated

Source: ClinicalTrials.gov. Data processed . See every multiple sclerosis study recruiting in Ann Arbor, MI on ClinicalTrials.gov.

Epilepsy studies recruiting in Ann Arbor

  1. A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

    • Phase 3
    • Ages 12 and older
    • All sexes
    Sponsor
    Xenon Pharmaceuticals Inc.
    Study site
    University of Michigan Hospitals
    Registry record
    NCT05667142 · updated
  2. ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome

    • Phase 1/2
    • Ages 2 to 12
    • All sexes
    Sponsor
    Ionis Pharmaceuticals, Inc.
    Study site
    University of Michigan Health System
    Registry record
    NCT07531745 · updated
  3. Diagnosing Epilepsy To EffeCT Change

    • No phase
    • Ages 18 to 75
    • All sexes
    Sponsor
    Epiminder America, Inc.
    Study site
    Michigan Medicine
    Registry record
    NCT07110337 · updated
  4. A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome

    • Phase 1/2
    • From 6 months, up to 17 years
    • All sexes
    Sponsor
    Encoded Therapeutics
    Study site
    Mott Children's Hospital
    Registry record
    NCT05419492 · updated
  5. Diagnosing Epilepsy To EffeCT Change Long-Term Follow-Up

    • Observational
    • Ages 18 to 75
    • All sexes
    Sponsor
    Epiminder America, Inc.
    Study site
    Michigan Medicine
    Registry record
    NCT07110454 · updated

Source: ClinicalTrials.gov. Data processed . See every epilepsy study recruiting in Ann Arbor, MI on ClinicalTrials.gov.

Migraine studies recruiting in Ann Arbor

  1. Study of EVO756 in Adults With Migraine

    • Phase 2
    • Ages 18 to 64
    • All sexes
    Sponsor
    Evommune, Inc.
    Study site
    Michigan Headache and Neurological Institute
    Registry record
    NCT07616128 · updated
  2. A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    TriGemX Bio, Inc.
    Study site
    Michigan Headache Pain & Neurological Institute
    Registry record
    NCT07645924 · updated
  3. A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    TriGemX Bio, Inc.
    Study site
    Michigan Headache Pain & Neurological Institute
    Registry record
    NCT07674654 · updated
  4. Randomized Study in Children and Adolescents With Migraine: Acute Treatment

    • Phase 3
    • Ages 6 to 17
    • All sexes
    Sponsor
    Pfizer
    Study site
    Michigan Head Pain & Neurological Institute
    Registry record
    NCT04649242 · updated
  5. Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine

    • Phase 3
    • Ages 6 to 17
    • All sexes
    Sponsor
    Pfizer
    Study site
    Michigan Head Pain and Neurological Institute
    Registry record
    NCT04743141 · updated
  6. A Study to Learn About the Safety of Taking an Additional Dose of the Medicine Rimegepant in Adults With Migraine

    • Phase 4
    • Ages 18 and older
    • All sexes
    Sponsor
    Pfizer
    Study site
    Michigan Headache & Neurological Institute
    Registry record
    NCT07609914 · updated
  7. A Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Pfizer
    Study site
    Michigan Headache & Neurological Institute
    Registry record
    NCT07729462 · updated
  8. A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years

    • Phase 3
    • Ages 12 to 17
    • All sexes
    Sponsor
    AbbVie
    Study site
    Michigan Headache & Neurological Institute /ID# 270942
    Registry record
    NCT06810505 · updated
  9. A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine

    • Phase 3
    • Ages 6 to 17
    • All sexes
    Sponsor
    AbbVie
    Study site
    Michigan Headache & Neurological Institute (MHNI) /ID# 247468
    Registry record
    NCT05711394 · updated

Source: ClinicalTrials.gov. Data processed . See every migraine study recruiting in Ann Arbor, MI on ClinicalTrials.gov.

Ask about studies near Ann Arbor

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

CNS Clinical Research does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 520-7418

or send a short form

How should we reach you?

Call